Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition

The purpose of this pre-screening study is to identify people who may be eligible for future clinical trials that test new drugs for Alzheimer’s disease (AD). Participants will be asked to perform a memory test and give a blood sample for the assessment of pTau217 blood biomarker that has been developed to help identify people who are likely to have AD. Participants will not receive any medication or therapeutic intervention in this study.

Trial phase

Other

Trial participation type

This trial is for clinical research of something other than a drug or device.

Principal investigator

A/Prof David Darby

Key inclusion data

Inclusion Criteria: Aged between 50 to 90 years old; Memory concerns reported by the participant or their study partner within the last year, with or without a previous clinical diagnosis of mild cognitive impairment (MCI) or dementia due to Alzheimer’s disease. Exclusion Criteria: Dependency in basic activities of daily living due to cognitive impairment; Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted); A diagnosis of but not limited to frontotemporal dementia, vascular dementia, Parkinson’s disease, seizure disorder or any neurological condition.